Fine Purdue Pharma? No. Nationalize It? Now We’re Talking.

The opioid manufacturer wants a global settlement. Americans need personal accountability. Making Purdue a public beneficiary trust company could yield some interesting options.

by

If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.

Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.

Join our community of supporters and make a donation today to help keep independent journalism thriving.